Effect of SVV-guided Fluid Therapy on Outcomes After Major Abdominal Surgery
- Conditions
- Goal-directed Fluid Therapy
- Interventions
- Device: the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device
- Registration Number
- NCT03940144
- Lead Sponsor
- Beijing Tongren Hospital
- Brief Summary
The investigators conduct this randomized assessor-blinded controlled trial to evaluate the effect of SVV-guided fluid therapy on postoperative morbidity and mortality in comparison with conventional fluid therapy after major abdominal surgery. Half of participants will receive GDFT perioperatively, and the others will receive conventional fluid therapy
- Detailed Description
Perioperative fluid management has been recognized as an important factor with an impact on postoperative recovery following major abdominal surgery. However, the optimal fluid management is difficult to achieve using standard parameters (e.g., heart rate \[HR\], blood pressure \[BP\], central venous pressure\[CVP\], or urine output) that poorly estimate preload and preload responsiveness. Goal-directed fluid therapy (GDFT) was proposed by introducing different hemodynamic variables into a dynamic perspective of individual fluid loading with or without vasoactive substances to reach predefined goal of optimal preload and/or oxygen delivery.There have been increasing numbers of studies evaluating the effect of perioperative GDFT on postoperative recovery following major abdominal surgery. However, the evidence for the beneficial effect of GDFT on postoperative recovery remains inconsistent.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
- Adult patients (aged 18 to 80 years)
- ASA I~III
- BMI:18~30kg／m2
- Procedures were considered major if listed for resection of gastrointestinal, gynecologic, and urologic cancer with tumor debulking, staging or reconstruction with a risk for significant surgical blood loss
- Patients under 18 years,
- pregnant or lactating woman
- patients with esophageal or gastric surgical history
- co-existing congestive heart failure; chronic lung disease; or renal or hepatic dysfunction (creatinine >50 % or liver enzymes >50 % of normal values), and arrhythmias-operative down staging using chemotherapy and/or radiation therapy
- patients undergoing emergency surgery
- patients with co-existing congestive heart failure; chronic lung disease; or renal or hepatic dysfunction (creatinine >50 % or liver enzymes >50 % of normal values), and arrhythmias
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description goal-directed fluid therapy the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device Stroke Volume variation (SVV)-guided fluid therapy Conventional fluid therapy the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device Conventional fluid therapy such as CVP and MAP guided fluid therapy
- Primary Outcome Measures
Name Time Method Length of hospital stay from the end of surgery to discharge from hospital up to 30 days after surgery from the end of surgery to discharge from hospital
GI function from the end of surgery to 30 days after surgery number of participants with I-FEED score \>6
- Secondary Outcome Measures
Name Time Method postoperative recovery quality 1 day, 3 days and 5 days after surgery QoR-15 :quality of recovery score : 0 worst recovery quality and 150 for best recovery
Postoperative complications from end of surgery to 30 days after surgery number of any complications after surgery
mortality from the end of surgery to 1 year after surgery death after surgery
postoperative pain score 1 day, 3 days and 5 days after surgery VAS for pain :0 no pain and 10 for worst pain
Trial Locations
- Locations (1)
Beijing Tongren Hospital
🇨🇳Beijing, Beijing, China